# Catalys Pacific

> Catalys Pacific is a VC fund in Fujisawa backing Biotechnology and Biopharma. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Fujisawa, Japan
- Total investments: 21
- Last investment: Sep 2025
- Lead investor: 38%
- Last fund: Feb 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/catalys-pacific
- Website: https://catalyspacific.com/

Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences. Founded in 2019, the firm's mission is to focus on providing healthcare solutions for patients worldwide through the creation of and investment in bioventure companies. Catalys Pacific is led by a global team versed in working closelywith its partners in academia, biotech, venture capital and the pharmaceutical industry in Japan and worldwide. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in Seattle, Washington.

## Contacts

5 contacts available for Catalys Pacific. Shizune tracks 7 team members at Catalys Pacific. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/catalys-pacific?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 24% |
| Biopharma | 4 | 19% |
| Pharmaceutical | 4 | 19% |
| Medical | 3 | 14% |
| Therapeutics | 3 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 29% |
| Seed | 4 | 19% |
| Series B | 3 | 14% |
| Private Equity | 1 | 5% |
| Venture - Series Unknown | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 33% |
| Japan | 2 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| BT Slingsby | Founder & Managing Partner | 12 | — |
| Ashwin Ram | Vice President | 0 | — |
| Ashwin Ram | Vice President | 0 | — |
| Hiromi Miwa | Junior Associate | 0 | — |
| Maki Haginoya | Junior Associate | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M | Series A | Sep 30, 2025 |  |
| Pathalys Pharma | Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $105M | Series B | Aug 20, 2024 |  |
| Renalys Pharma | Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients. | $38.5M | Series A | Jul 17, 2024 |  |
| Arialys Therapeutics | Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment. | $58M | Seed | Sep 12, 2023 |  |
| Pathalys Pharma | Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $150M | Series A | Jan 18, 2023 |  |
| Mineralys Therapeutics | Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M | Series B | Jun 08, 2022 |  |
| Mineralys Therapeutics | Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M | Series B | Jun 08, 2022 |  |
| Aculys Pharma | Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $22.9M | Series B | Mar 27, 2022 |  |
| Aculys Pharma | Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $22.9M | Series B | Mar 27, 2022 |  |
| Aculys Pharma | Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $59.9M | Series A | Oct 28, 2021 |  |

10 of 21 investments shown.

## Co-investors
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 10 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 8 deals together
- [HBM Partners](https://shizune.co/investors/profile/hbm-partners) — VC Fund, 8 deals together
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 4 deals together
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund, 4 deals together
- [DaVita Venture Group](https://shizune.co/investors/profile/davita-venture-group) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Catalys Pacific invest in?

Catalys Pacific invests primarily in Biotechnology, Biopharma and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Catalys Pacific?

Public channels for Catalys Pacific include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Catalys Pacific?

The team at Catalys Pacific includes BT Slingsby (Founder & Managing Partner), Ashwin Ram (Vice President) and Ashwin Ram (Vice President), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co